Listing of Opportunities for General Public:

A brief listing of studies and work opportunities for the public is included here.
For a complete listing of (many more) messages for SIMD members, please LOG IN, here or above.


There is currently only one public listing in this section.

19 October, 2019

Study Opportunity:  Applied Therapeutics is currently enrolling a Phase 1/2 study of AT-007 in adults (age 18 and older) with galactosemia. The study, called ACTION-Galactosemia, will investigate safety and pharmacokinetics (PK) of AT-007, a central nervous system (CNS) penetrant Aldose Reductase Inhibitor in healthy volunteers, and will then explore safety, PK and biomarker effects in adult subjects with Galactosemia. If you are a patient or family member interested in receiving information about this trial, please email to galactosemia@appliedtherapeutics.com. For more information about the study, please visit: https://www.appliedtherapeutics.com/galactosemia,

For a complete listing of (many more) messages for SIMD members, please LOG IN, here or above.